IL-28B (IFN-λ3) and IFN-α synergistically inhibit HCV replication.

Area of Science:

• Virology
• Immunology
• Genetics

Background:

• Interleukin-28B (IL-28B) gene variations influence hepatitis C treatment outcomes.
• Mechanisms linking IL-28B polymorphisms to host antiviral responses remain unclear.

Purpose of the Study:

• To investigate the in vitro anti-HCV effects of interferon-lambda 3 (IFN-λ3) and interferon-alpha (IFN-α).
• To compare the gene expression profiles induced by IFN-λ3 and IFN-α.
• To evaluate the combined effect of IFN-λ3 and IFN-α on HCV RNA replication.

Main Methods:

• Utilized the HCV 1b and 2a replicon system to assess viral RNA replication.
• Compared concentration- and time-dependent inhibition by IFN-λs and IFN-α.
• Analyzed gene expression changes using cDNA microarray analysis.
• Assessed synergistic effects of combined IFN-λ3 and IFN-α treatment.

Main Results:

• IFN-λs demonstrated concentration- and time-dependent inhibition of HCV RNA replication.
• Combined IFN-λ3 and IFN-α exhibited synergistic anti-HCV activity.
• No synergistic enhancement was observed for ISRE activity or ISG upregulation.
• IFN-λ3 induced later and longer-lasting gene expression compared to IFN-α.
• Combined IFN administration prolonged interferon-stimulated gene expression.

Conclusions:

• IFN-α and IFN-λ3 demonstrate synergistic anti-HCV activity in vitro.
• Differential kinetics of gene upregulation by IFN-α and IFN-λ3 may contribute to their combined antiviral efficacy.